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ABSTRACT
Objectives Rheumatoid arthritis (RA) shares some 
similar clinical and pathological features with juvenile 
idiopathic arthritis (JIA); indeed, the strategy of 
investigating whether RA susceptibility loci also confer 
susceptibility to JIA has already proved highly successful 
in identifying novel JIA loci. A plethora of newly validated 
RA loci has been reported in the past year. Therefore, 
the aim of this study was to investigate these single 
nucleotide polymorphisms (SNP) to determine if they 
were also associated with JIA.
Methods Thirty-four SNP that showed validated 
association with RA and had not been investigated 
previously in the UK JIA cohort were genotyped in JIA 
cases (n=1242), healthy controls (n=4281), and data 
were extracted for approximately 5380 UK Caucasian 
controls from the Wellcome Trust Case–Control 
Consortium 2. Genotype and allele frequencies were 
compared between cases with JIA and controls using 
PLINK. A replication cohort of 813 JIA cases and 3058 
controls from the USA was available for validation of any 
signifi cant fi ndings.
Results Thirteen SNP showed signifi cant association 
(p<0.05) with JIA and for all but one the direction of 
association was the same as in RA. Of the eight loci that 
were tested, three showed signifi cant association in the 
US cohort.
Conclusions A novel JIA susceptibility locus was 
identifi ed, CD247, which represents another JIA 
susceptibility gene whose protein product is important 
in T-cell activation and signalling. The authors have also 
confi rmed association of the PTPN2 and IL2RA genes 
with JIA, both reaching genome-wide signifi cance in the 
combined analysis.
Juvenile idiopathic arthritis (JIA) is a collective 
term that encompasses all forms of arthritis, with 
an unknown cause, that have an onset before the 
age of 16 years and that persist for more than 6 
weeks.1 There are seven disease categories as 
deﬁ ned by the International League of Associations 
for Rheumatology (ILAR) classiﬁ cation criteria2 
and, while there is heterogeneity between the 
subtypes in terms of disease presentation, clini-
cal symptoms and prognosis, they do appear to 
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share genetic susceptibility risk factors.3 4 JIA is a 
relatively rare disease and as such it has taken lon-
ger to collect the large and appropriately powered 
sample sizes required for genome-wide associa-
tion studies (GWAS). International collaborations 
have been established and GWAS for JIA have 
been performed or are in progress.5 However, in 
the meantime, there are other approaches that can 
be used to identify genetic risk factors for JIA. We 
and other investigators have successfully exploited 
the fact that many complex auto immune diseases 
share common genetic risk factors; for example, 
protein tyrosine phosphatase non-receptor 22 
(PTPN22) and interleukin 2 receptor α (IL2RA) 
both confer susceptibility to multiple auto immune 
diseases, such as type 1 diabetes (T1DM), rheu-
matoid arthritis (RA) and autoimmune thyroid 
disease, and markers in both these genes have 
been associated with JIA.4 6 Of the autoimmune 
diseases, RA shares the most similar clinical and 
pathological features with JIA, and we have pre-
viously reported considerable overlap in genetic 
susceptibility loci for the two diseases, ﬁ nd-
ing evidence of association for four loci (STAT4, 
TRAF1/C5, TNFAIP3 and PRKCQ) with JIA.7 The 
ﬁ rst three of which have further evidence of asso-
ciation with JIA in independent cohorts.8 9 In the 
past few years many additional RA loci have been 
identiﬁ ed10–12 and these represent excellent candi-
date JIA loci. Therefore the aim of this study was 
to investigate whether newly identiﬁ ed RA sus-
ceptibility loci also confer susceptibility to JIA.
MATERIALS AND METHODS
SNP selection
Single-nucleotide polymorphisms (SNP) that 
showed validated association with RA and had not 
been investigated previously in the UK JIA cohort 
were selected for genotyping. These were identiﬁ ed 
from three recent RA publications.10–12 The ﬁ rst was 
a GWAS in cases and controls from North America 
and from that study SNP in REL (rs13031237), BLK 
(rs2736340) and CTLA4 (rs231735) were selected 
for genotyping.10 The second was a meta-analysis 
of published GWAS in which 13 novel RA SNP 
were identiﬁ ed.11 Finally, a second larger meta-
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from analysis. SNP were genotyped using the Affymetrix 
genome-wide human SNP array 6.0. The study had full ethics 
committee approval (CCHMC Institutional Review Board) and 
was fully compliant with the Declaration of Helsinki.5
Statistical analysis
Power calculations were performed using QUANTO to calculate 
the prior probability of detecting association in the current UK 
sample size at the allele frequency and effect sizes reported pre-
viously in RA.10–12 Calculations assumed a log-additive model 
and an α value of 0.05. Power calculations were also performed 
to determine the power of the US cohort to validate the ﬁ ndings 
of the UK cohort. Genotype and allele frequencies were com-
pared between cases with JIA and controls using the Cochrane–
Armitage trend test implemented in PLINK18 and allelic OR and 
their 95% CI were calculated.
Analysis was performed in all JIA cases for the UK cohort ini-
tially but then the analysis was restricted to subtypes equivalent 
to those in the US cohort (see supplementary table 1, available 
online only) to allow for comparison of OR and for combining 
the data in a meta-analysis.
RESULTS
The JIA case number after quality control was 1229. The power 
calculation for each SNP is shown in supplementary table 3 
(available online only).
Of the 34 SNP selected for genotyping, four failed to genotype 
(rs892188 (ICAM1), rs934734 (SPRED2), rs7155603 (BATF) and 
rs840016 (CD247), although a SNP in the CD247 gene identi-
ﬁ ed in the Raychaudhuri study was genotyped,11 rs1773560, 
which has r2=0.68 with rs840016. Therefore, there were 30 SNP 
for analysis. The SNP in IRF5 (rs10488631) failed genotyping in 
the UKRAG control dataset, therefore the comparison was lim-
ited to the WTCCC2 control data while conversely the SNP in 
TAGAP (rs394581) failed to genotype in the WTCCC2 control 
cohort so the comparison was limited to the UKRAG control 
dataset.
Thirteen SNP showed nominal evidence of association with 
JIA (p<0.05) (table 1). Results for all SNP are provided in supple-
mentary table 2 (available online only). Figure 1 shows a com-
parison between the association analysis results in RA and JIA. 
For all but one (NHLH2) of the 13 loci the direction of associa-
tion was the same as that observed in the RA studies, with simi-
lar OR and sometimes stronger effect sizes in JIA (ﬁ gure 1).
Of the 13 loci that showed nominal association with JIA in our 
UK cohort, eight had genotype data available in the US valida-
tion cohort (table 2). There were no data for the IL2, ANKRD55, 
C5orf30 or the IRF5 SNP. Of the eight SNP, three (rs1773560 in 
CD247, rs706778 in IL2RA and rs7234029 in PTPN2) showed 
association with JIA in the US cohort, and meta-analysis of the 
two cohorts strengthened the association.
DISCUSSION
The now well-established overlap of genetic susceptibility 
risk factors across quite clinically and phenotypically different 
autoimmune diseases has been an exciting discovery that has 
emerged from the GWAS era. It suggests there will be shared 
pathogenic pathways and the potential for shared therapies for 
these diseases. Furthermore, it can be exploited as a strategy 
for the identiﬁ cation of novel risk factors for related autoim-
mune diseases, including JIA. There is already compelling evi-
dence that many susceptibility loci are shared between RA and 
JIA (PTPN22,5 6 IL2RA,4 19 STAT4,5 7 20 IL2,5 13 21 TRAF1/C57 20 
analysis of RA cases and controls identiﬁ ed a further 21 SNP 
with replicated association with RA. Of these, 10 had achieved 
genome-wide signiﬁ cance in the combined analysis and 11 had 
highly suggestive evidence of association although not exceed-
ing the threshold for claims of genome-wide signiﬁ cance.12 
Results for three of these SNP (in IL2RA, AFF3 and c12orf30) had 
previously been investigated in the UK JIA cohort,4 13 14 and so 
were not included in this study. In total, therefore, 34 SNP were 
selected for genotyping.
Subjects
UK cohort
DNA was available for 1242 UK Caucasian JIA patients from 
three sources: The British Society for Paediatric and Adolescent 
Rheumatology national repository of JIA (n=654); a group of UK 
Caucasian patients with long-standing JIA (n=201), described 
previously,15 and a third cohort collected as part of the Childhood 
Arthritis Prospective study, a prospective inception cohort study 
of JIA cases from ﬁ ve centres across the UK (n=387).16 JIA cases 
were classiﬁ ed according to ILAR criteria2 (see supplementary 
table 1, available online only). Healthy Caucasian control DNA 
samples (n=4281) were available from ﬁ ve centres in the UK, 
collected as part of the UK RA genetics (UKRAG) consortium, as 
described previously.17 All individuals were recruited with eth-
ics approval and provided informed consent (North-West Multi-
Centre Research Ethics Committee (MREC 99/8/84) and the 
University of Manchester Committee on the Ethics of Research 
on Human Beings). Additional control genotyping data were 
extracted from the Wellcome Trust Case–Control Consortium 
2 (WTCCC2) European Genome–Phenome Archive website 
(http://www.ebi.ac.uk/ega/). SNP had been genotyped on either 
the Illumina (n=5200) or Affymetrix (n=5380) platform. If a SNP 
had been genotyped on both platforms then the results from the 
analysis with the larger control set was presented.
All SNP were genotyped in the UK JIA cases using the 
Sequenom iPlex MassARRAY platform according to manufac-
turer’s instructions (Sequenom, San Diego, California, USA; 
http://www.sequenom.com/). A 90% sample quality control 
rate and 90% genotyping success rate was imposed.
US cohort
For validation of the ﬁ ndings in the UK cohort, genotype infor-
mation was available from a cohort of 813 JIA cases and 3058 
controls from the USA. These data are from a GWAS, which 
has previously been investigated for autoimmune overlap.5 For 
the JIA children, with polyarticular (rheumatoid factor nega-
tive) and oligoarticular JIA, approximately 95% of the cases 
were recruited at the Cincinnati Children’s Hospital Medical 
Center (CCHMC) or as part of a National Institute of Arthritis 
and Musculoskeletal and Skin Diseases-supported JIA affected 
sibpair registry. The remaining cases were contributed by 
collaborating centres that included the Children’s Hospital 
of Wisconsin, Schneider Children’s Hospital and Children’s 
Hospital of Philadelphia. JIA cases were classiﬁ ed according to 
ILAR criteria2 and comprised cases from three subtypes of JIA 
(see supplementary table 1, available online only). The control 
cohort (n=3058) comprised 658 healthy children aged between 
3 and 18 years, recruited from the general population to repre-
sent the geographical region served by CCHMC. In addition, 
2400 healthy controls of European ancestry were genotyped 
at the Broad Institute on the Affymetrix SNP array 6.0, which 
have been collected as part of the Molecular Genetics of 
Schizophrenia GWAS. Both cases and controls were subjected 
to principal component analysis, and any outliers were excluded 
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amongst others). In this study we have identiﬁ ed and validated 
association with three novel loci, originally associated with RA.
One of these identiﬁ es a new JIA susceptibility gene, CD247, 
a good candidate for JIA as it encodes the zeta chain of the T-cell 
receptor–CD3 complex and adds another gene to the list of JIA 
susceptibility loci that play a role in T-cell activation and signal-
ling (PTPN22, IL2RA, PTPN2, SH2B3 and STAT4). In addition 
to the reported associations with RA, SNP within CD247 have 
also been associated with coeliac disease22 and with systemic 
sclerosis.23 The JIA-associated SNP is in complete linkage dis-
equilibrium (LD) (r2=1) with the SNP associated with systemic 
sclerosis (rs2056626) and in strong LD (r2=0.86) with the SNP 
most signiﬁ cantly associated with coeliac disease (rs864537). 
The risk variant of the SNP has also been correlated with cis 
gene expression of CD247.22 24
We found strong evidence for association of a SNP, rs7234029, 
in the protein tyrosine phosphatase non-receptor 2 (PTPN2) 
gene with JIA in our UK cohort. There is already replicated evi-
dence for association of SNP within this gene with JIA in US and 
German cohorts.5 In the US study, the SNP with the strongest 
association was also rs7234029, and it reached genome-wide 
levels of signiﬁ cance; in addition there was association with 
four additional SNP. Meta-analysis of the UK JIA cohort study 
with the US data further established PTPN2 as an important JIA 
susceptibility locus (combined p value 8.1×10-13). The PTPN2 
gene has been associated with multiple autoimmune diseases, 
including T1DM,25 26 Graves’ disease,25 Crohn’s disease27 and 
coeliac disease.26 In T1DM, ﬁ ne-mapping suggests there are 
two independently associated SNP, rs45450798 and rs478582.26 
These SNP are only in modest LD with rs7234029. Further ﬁ ne-
mapping of the gene in RA and JIA will be required to iden-
tify the causal variant, whether there are multiple independent 
effects and whether the associations are the same across the dif-
ferent autoimmune diseases. PTPN2 encodes a protein tyrosine 
phosphatase, similar to PTPN22, which also plays a role in the 
activation and regulation of T and B cells.
SNP within IL2RA have previously been shown to be associ-
ated with JIA using these same UK and US cohorts4 as well as 
many other autoimmune diseases such as RA,19 T1DM28 and 
multiple sclerosis,29 but the association is complex with mul-
tiple independent effects and different associations across the 
different diseases. The novel SNP associated here is in only Ta
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Figure 1 Plot of OR for minor allele for 13 loci showing nominal 
evidence of association with juvenile idiopathic arthritis (JIA), 
comparison with rheumatoid arthritis (RA). Odds ratios obtained from 
Raychaudhuri et al,11 Stahl et al12 and Gregersen et al.10
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weak LD with the most associated SNP from the previous 
study, rs2104286, r2=0.24. However, conditional logistic regres-
sion analysis in the UK dataset suggests that rs2104286 is driv-
ing the association with JIA. After conditioning on rs2104286 
there was no signiﬁ cant association at rs706778, whereas after 
conditioning on rs706778, there was still signiﬁ cant association 
at rs2104286 (data not shown). Meta-analysis of the UK and US 
studies found highly signiﬁ cant evidence for association with 
JIA (combined p value 3.3×10−8), which now brings this locus to 
a genome-wide signiﬁ cance level.
In the initial analysis of the UK cohort only the most signiﬁ cant 
association was for a SNP in the protein-tyrosine phosphatase 
receptor type C (PTPRC) gene, which again is a promising can-
didate gene. This gene encodes the common leucocyte antigen, 
CD45, which is a haemopoietic cell-speciﬁ c tyrosine phos-
phatase. CD45 is essential for the activation of T and B cells by 
mediating cell-to-cell contacts and regulating protein-tyrosine 
kinases involved in signal transduction.30 However, this was not 
validated in the US cohort; in fact, there was a trend towards 
an association but in the opposite direction. There are a number 
of possible reasons for this, including a false positive in the ini-
tial UK dataset, a false negative in the US dataset, unrecognised 
population stratiﬁ cation, phenotypic heterogeneity and differ-
ent environmental exposures. Analysis of this SNP in additional 
larger cohorts is required to conﬁ rm or refute association with 
this locus.
The JIA association ﬁ ndings were not validated in the US 
cohort for CD2, RBPJ, BLK and ORMDL3, and only ORMDL3 
remained signiﬁ cant in the combined analysis. The US cohort 
was underpowered to detect an effect with all of these loci apart 
from ORMDL3 (see supplementary table 3, available online 
only), therefore further validation is needed.
In addition it should be noted that for the 16 SNP that were not 
signiﬁ cantly associated with JIA in this study, we had between 
29% and 99% power to detect an association; therefore, for 
some of these SNP, larger datasets and meta-analyses will be 
required to exclude association with JIA completely.
JIA is a heterogeneous disease and it may be expected that 
there are genetic differences across the JIA subtypes and some 
subtype-speciﬁ c effects have been identiﬁ ed.31 32 In this study 
our strategy was to look for shared autoimmune or inﬂ amma-
tory arthritis susceptibility loci, and it would be interesting to 
investigate whether these associations are common to all JIA 
subtypes or are restricted to some subtypes. However, stratiﬁ ed 
analysis leads to small sample sizes for many of the subtypes 
and further issues with multiple testing. Larger cohorts of the 
ILAR subtypes are required to improve the power to detect any 
subtype-speciﬁ c effects. We have stratiﬁ ed our analysis just to 
investigate the oligoarthritis and rheumatoid factor-negative 
polyarthritis subtypes as these were the subtypes comprising 
the validation cohort.
For all these loci identiﬁ ed for JIA we have only tested one 
SNP, the SNP most signiﬁ cantly associated with RA from 
GWAS. In most cases for the genes identiﬁ ed to date for RA 
and other autoimmune diseases, the actual causal variant has 
yet to be identiﬁ ed, which may reduce the power of this study 
even further, so further ﬁ ne-mapping of the genes/regions is 
now required.
In conclusion, the strategy of testing loci identiﬁ ed in other 
autoimmune diseases, such as RA, for association with JIA is 
proving successful in the identiﬁ cation of novel JIA loci and is 
a complementary approach to the hypothesis-free methods 
of GWAS. In the past few years we have investigated 45 loci 
that confer susceptibility to RA for association with JIA.7 13 33 Ta
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Of these, 22 show association (p<0.05) with JIA in our UK 
cohort and 11 of these show validated association with JIA in 
independent cohorts.5 8 9 34 35 Clearly, there is a selection bias 
given the strategy used to select SNP to test; however, there still 
remains quite considerable overlap between two distinct clinical 
entities. Many of these loci also confer susceptibility to other 
autoimmune diseases and may thus represent genes control-
ling general immune function, the defects of which may lead 
to an enhanced autoimmune response. Despite the success of 
this approach in identifying novel JIA loci, large well-powered 
GWAS will be required to identify disease-speciﬁ c loci for JIA 
and its subtypes.
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